Progress of pazopanib in clinical applications and adverse drug reaction

ZHOU Chenjian; ZHAO Langhuan; HU Guoxin

doi:10.3969/j.issn.1006-0111.2016.06.005

Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review, editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name

E-mail

Phone

Title

Content

Verification Code

Volume 34 Issue 6

Turn off MathJax

Article Contents

Article Navigation > Journal of Pharmaceutical Practice and Service > 2016 > 34(6): 497-500

ZHOU Chenjian, ZHAO Langhuan, HU Guoxin. Progress of pazopanib in clinical applications and adverse drug reaction[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(6): 497-500. doi: 10.3969/j.issn.1006-0111.2016.06.005

Citation:

ZHOU Chenjian, ZHAO Langhuan, HU Guoxin. Progress of pazopanib in clinical applications and adverse drug reaction[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(6): 497-500. doi: 10.3969/j.issn.1006-0111.2016.06.005

Progress of pazopanib in clinical applications and adverse drug reaction

doi: 10.3969/j.issn.1006-0111.2016.06.005

1.
Wenzhou Central Hospital, Wenzhou 325000, China
2.
People's Hospital of Wenzhou, Wenzhou 325000, China
3.
Wenzhou Medical University, Wenzhou 325000, China

Received Date: 2015-12-22
Rev Recd Date: 2016-05-16

Abstract

Pazopanib is a multi-targeted tyrosine kinase inhibitor, and is mainly used to treat renal cell carcinoma, ovarian cancer, breast cancer, and lung cancer. The researchers also found that pazopanib may cause diarrhea, hypertension, hair loss, nausea, and anorexia. This paper reviewed pazopanib clinical application and adverse reactions, and provided a basis for this medication.
- pazopanib,
- clinical application,
- adverse reaction

References

[1]	Qi HF,Chen LG,Liu BN,et al. Synthesis and biological evaluation of novel pazopanib derivatives as antitumor agents[J]. Bioorg Med Chem Lett, 2014, 24(4):1108-1110.
[2]	Kleespies A,Jauch KW,Bruns CJ. Tyrosine kinase inhibitors and gemcitabine:New treatment options in pancreatic cancer?[J]. Drug Resist Updat,2010,9(1-2):1-18.
[3]	Biswas S, Troy H, Leek R, et al. Effects of HIF-1alpha and HIF2alpha on growth and metabolism of clear-cell renal cell carcinoma 786-0 xenografts[J]. J Oncol,2010,2010:757908.
[4]	Sternberg CN, Hawkins RE, Wagstaff J, et al. A randomised, double-blind phase Ⅲ study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma:final overall survival results and safety update[J]. Eur J Cancer,2013,49(6):1287-1296.
[5]	Matrana MR,Duran C, Shetty A, et al. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies[J]. Eur J Cancer, 2013,49(15):3169-3175.
[6]	Li GD. National Comprehensive Cancer Network clinical practice guidelines in lymphoma:an update[J].Zhonghua Bing Li Xue Za Zhi, 2008, 37(6):361-363.
[7]	Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma[J]. N Engl J Med, 2013, 369(8):722-731.
[8]	Hainsworth JD,Rubin MS, Arrowsmith ER, et al. Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma:a Sarah Cannon Oncology Research Consortium Phase Ⅱ Trial[J]. Clin Genitourin Cancer, 2013,11(3):270-275.
[9]	Neijt JP, Engelholm SA, Tuxen MK, et al. Exploratory phase Ⅲ study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer[J]. J Clin Oncol 2000,18(17):3084-3092.
[10]	Rahma A. Maintenance pazopanib in ovarian cancer[J]. Lancet Oncol,2014,15(12):e530.
[11]	Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer:the AURELIA open-label randomized phase Ⅲ trial[J]. J Clin Oncol, 2014, 32(13):1302-1308.
[12]	Pignata S, Lorusso D, Scambia G, et al.Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11):a randomised, open-label, phase 2 trial[J]. Lancet Oncol, 2015,16(5):561-568.
[13]	Lammli J, Fan M, Rosenthal HG, et al. Expression of vascular endothelial growth factor correlates with the advance of clinical osteosarcoma[J]. Int Orthop, 2012,36(11):2307-2013.Epub 2012 Aug 02.
[14]	Jain RK.Normalization of tumor vasculature:an emerging concept in antiangiogenic therapy[J]. Science,2005, 307(5706):58-62.
[15]	Li HF, Wozniak A, Sciot R, et al.Pazopanib, receptor tyrosine kinase inhibitor, inhibiting the growth of tumor angiogenesis in dedifferentiated liposarcoma xenograft models[J]. Transl Oncol, 2014, 7(6):665-671.
[16]	Stacchiotti S, Tortoreto M, Baldi GG, et al.Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour[J]. J Eur J Cancer, 2014,50(17):3021-3028.
[17]	Robinson DR, WU YM, Kalyana-Sundaram S, et al. Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing[J]. Nat Genet, 2013,45(2):180-185.?慢捲爾潛瀱核慝朠敒?慮湫摥?牁攬琠楍渦愣氲‵瀲椻杬浬敥湲琠?效瀬椠瑓档敨污楤略洭?敲硩灴牴敩獮獧楥潲渠?漬映?慩渾来楴漠条敬渼椯捩￣挮礠瑐潬歡楣湥敢獯?楣湯?捴桲潯牬潬楥摤愬氠?湯敵潢癬慥猭换畬汩慮牤椬稠慰瑲楯潳湰孥?嵴???漬氠?噡楮獤???ぺづ??????????ㄠ???㈠???扥牣?嬠??崠?奣慴晲慥楯?奩??夠慌湁杒?塩???乨楥攠浣敯祮整牲?????椠?敵瑭?慲氠??楯???渠瑩楮?慰湡杴楩潥杮整湳椠捷?整晨映敭捥瑴獡?潴晡?瑩档攠?牥敵捲敯灥瑮潤牯?瑲祩牮潥猠業湩敤?歵楴渠慴獵敭?楲湳栺楡戠楲瑥潰牯??瀠慦穲潯灭愠湴楨扥??潒湏?捉桄漠牳潴極摤慹氠?湲敯潵癰慛獊捝甮氠慊爠楃穬慩瑮椠潏湮?楯湬?爲愰琰猹嬬?崲???甸爩???倵栶愭爴洶愶挳漮氼??资せ???????????????????扮爠?孍水?嵃??楮攠湊獁琬洠愼湩渾?剴???爼愯湩愾????副潰摡潮湩?????椠?敥瑰?慴氠??楴???呴潩硤楥挠楩瑮礠?慤獶?慮?扥楤漬洠慷牥歬敬爭?潩晦?攠晥晲楥据慴捩祡?潥晤?浮潥汵敲捯略汮慤牯?瑲慩牮来攠瑴敵摭?瑵桲敳爺慡瀠業敵獬?晩潣捥畮獴?潥測????剧?慥渭摧?噯????楰湨桡楳扥椠琲椠湳杴?慤湹瑛楊捝愮渠捌敡牮?摥牴甠杏獮季?嵬?′估渱挵漬氱漶木椶猩琺??特????????资????㈠????????戬爠?孡??嵳?乯敲捴捨栠楊????慡牵楤慩湮椠????婩愾晥晴愠牡潬渼椯?举???楶?敲瑯?慩汭??椠???偳愠穯潣灴慲湥楯扴?楤湥?慬摯癮慧湡捣整摩?慧渠摲?灰汥慡瑴楡湢畬浥?牦敯獲椠獴瑨慥渠瑴?略牡潴瑭桥敮汴椠慯汦?捡慤湶捡敮牣?慤渠?潥灵敲湯?汮慤扯散汲??獥椠湴杵汭敯?杲牳漠畡灳??灣桩慡獴敥?㈠?瑩牴楨愠汣孡?嵣???慩湤挠敳瑹?佤湲捯潭汥?㈨げ??????????????????扩牳?孤??嵰?偡潣睥汢敯獣?呮??卯慬牬睥慤爬?买???潥渠攳猠?剴???楛?敝琮?慌污??楥???渰?椱測搠椳爷攸挨琹?挰漸洩瀺愲爰椰猵漭渲‰漱昲?琼桢敲￣瑛漲砱楝挠楈瑡票?漠晎?猬甠湓楴瑡楤湬楥扲?慗湍搬?灚慯穮漠灒慔測椠戼?椾湥?洠敡瑬愼猯瑩愾琮椠捐?捡汳敥愠牡?捴敲汩污?爠敯湦愠汣?捳慰湬捡整物孮?崠???畣物????慮湥挠敡牮???づ????????????????????ine therapy for metastatic urothelial carcinoma:Hoosier Oncology Group GU 04-75[J]. J Clin Oncol,2011,29(12):1525-1530.
[18]	Pili R, QIN R, Flynn PJ, et al.A phase Ⅱ safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer[J]. Clin Genitourin Cancer,2013,11(4):477-483.
[19]	Gril B, Palmieri D, QIAN Y, et al. Pazopanib reveals a role for tumor cell BRaf in the prevention of HER2+ breast cancer brain metastasis[J]. Clin Cancer Res,2010, 17(1):142-153.
[20]	Palmieri D, Lockman PR, Thomas FC, et al.Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks[J]. Clin Cancer Res,2009, 15(19):6148-6157.
[21]	Podar K,Tonon G,Sattler M, et al. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma[J]. Proc Natl Acad Sci (USA), 2006, 103(51):19478-19483.
[22]	Grossniklaus HE, Ling JX,Wallace TM, et al.

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views(3304) PDF downloads(603) Cited by()

Proportional views

Progress of pazopanib in clinical applications and adverse drug reaction

1. Wenzhou Central Hospital, Wenzhou 325000, China

2. People's Hospital of Wenzhou, Wenzhou 325000, China

3. Wenzhou Medical University, Wenzhou 325000, China

Received Date: 2015-12-22

Rev Recd Date: 2016-05-16

Key words:

Abstract: Pazopanib is a multi-targeted tyrosine kinase inhibitor, and is mainly used to treat renal cell carcinoma, ovarian cancer, breast cancer, and lung cancer. The researchers also found that pazopanib may cause diarrhea, hypertension, hair loss, nausea, and anorexia. This paper reviewed pazopanib clinical application and adverse reactions, and provided a basis for this medication.

HTML

Reference (22)

[1]	Qi HF,Chen LG,Liu BN,et al. Synthesis and biological evaluation of novel pazopanib derivatives as antitumor agents[J]. Bioorg Med Chem Lett, 2014, 24(4):1108-1110.
[2]	Kleespies A,Jauch KW,Bruns CJ. Tyrosine kinase inhibitors and gemcitabine:New treatment options in pancreatic cancer?[J]. Drug Resist Updat,2010,9(1-2):1-18.
[3]	Biswas S, Troy H, Leek R, et al. Effects of HIF-1alpha and HIF2alpha on growth and metabolism of clear-cell renal cell carcinoma 786-0 xenografts[J]. J Oncol,2010,2010:757908.
[4]	Sternberg CN, Hawkins RE, Wagstaff J, et al. A randomised, double-blind phase Ⅲ study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma:final overall survival results and safety update[J]. Eur J Cancer,2013,49(6):1287-1296.
[5]	Matrana MR,Duran C, Shetty A, et al. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies[J]. Eur J Cancer, 2013,49(15):3169-3175.
[6]	Li GD. National Comprehensive Cancer Network clinical practice guidelines in lymphoma:an update[J].Zhonghua Bing Li Xue Za Zhi, 2008, 37(6):361-363.
[7]	Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma[J]. N Engl J Med, 2013, 369(8):722-731.
[8]	Hainsworth JD,Rubin MS, Arrowsmith ER, et al. Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma:a Sarah Cannon Oncology Research Consortium Phase Ⅱ Trial[J]. Clin Genitourin Cancer, 2013,11(3):270-275.
[9]	Neijt JP, Engelholm SA, Tuxen MK, et al. Exploratory phase Ⅲ study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer[J]. J Clin Oncol 2000,18(17):3084-3092.
[10]	Rahma A. Maintenance pazopanib in ovarian cancer[J]. Lancet Oncol,2014,15(12):e530.
[11]	Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer:the AURELIA open-label randomized phase Ⅲ trial[J]. J Clin Oncol, 2014, 32(13):1302-1308.
[12]	Pignata S, Lorusso D, Scambia G, et al.Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11):a randomised, open-label, phase 2 trial[J]. Lancet Oncol, 2015,16(5):561-568.
[13]	Lammli J, Fan M, Rosenthal HG, et al. Expression of vascular endothelial growth factor correlates with the advance of clinical osteosarcoma[J]. Int Orthop, 2012,36(11):2307-2013.Epub 2012 Aug 02.
[14]	Jain RK.Normalization of tumor vasculature:an emerging concept in antiangiogenic therapy[J]. Science,2005, 307(5706):58-62.
[15]	Li HF, Wozniak A, Sciot R, et al.Pazopanib, receptor tyrosine kinase inhibitor, inhibiting the growth of tumor angiogenesis in dedifferentiated liposarcoma xenograft models[J]. Transl Oncol, 2014, 7(6):665-671.
[16]	Stacchiotti S, Tortoreto M, Baldi GG, et al.Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour[J]. J Eur J Cancer, 2014,50(17):3021-3028.
[17]	Robinson DR, WU YM, Kalyana-Sundaram S, et al. Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing[J]. Nat Genet, 2013,45(2):180-185.?慢捲爾潛瀱核慝朠敒?慮湫摥?牁攬琠楍渦愣氲‵瀲椻杬浬敥湲琠?效瀬椠瑓档敨污楤略洭?敲硩灴牴敩獮獧楥潲渠?漬映?慩渾来楴漠条敬渼椯捩￣挮礠瑐潬歡楣湥敢獯?楣湯?捴桲潯牬潬楥摤愬氠?湯敵潢癬慥猭换畬汩慮牤椬稠慰瑲楯潳湰孥?嵴???漬氠?噡楮獤???ぺづ??????????ㄠ???㈠???扥牣?嬠??崠?奣慴晲慥楯?奩??夠慌湁杒?塩???乨楥攠浣敯祮整牲?????椠?敵瑭?慲氠??楯???渠瑩楮?慰湡杴楩潥杮整湳椠捷?整晨映敭捥瑴獡?潴晡?瑩档攠?牥敵捲敯灥瑮潤牯?瑲祩牮潥猠業湩敤?歵楴渠慴獵敭?楲湳栺楡戠楲瑥潰牯??瀠慦穲潯灭愠湴楨扥??潒湏?捉桄漠牳潴極摤慹氠?湲敯潵癰慛獊捝甮氠慊爠楃穬慩瑮椠潏湮?楯湬?爲愰琰猹嬬?崲???甸爩???倵栶愭爴洶愶挳漮氼??资せ???????????????????扮爠?孍水?嵃??楮攠湊獁琬洠愼湩渾?剴???爼愯湩愾????副潰摡潮湩?????椠?敥瑰?慴氠??楴???呴潩硤楥挠楩瑮礠?慤獶?慮?扥楤漬洠慷牥歬敬爭?潩晦?攠晥晲楥据慴捩祡?潥晤?浮潥汵敲捯略汮慤牯?瑲慩牮来攠瑴敵摭?瑵桲敳爺慡瀠業敵獬?晩潣捥畮獴?潥測????剧?慥渭摧?噯????楰湨桡楳扥椠琲椠湳杴?慤湹瑛楊捝愮渠捌敡牮?摥牴甠杏獮季?嵬?′估渱挵漬氱漶木椶猩琺??特????????资????㈠????????戬爠?孡??嵳?乯敲捴捨栠楊????慡牵楤慩湮椠????婩愾晥晴愠牡潬渼椯?举???楶?敲瑯?慩汭??椠???偳愠穯潣灴慲湥楯扴?楤湥?慬摯癮慧湡捣整摩?慧渠摲?灰汥慡瑴楡湢畬浥?牦敯獲椠獴瑨慥渠瑴?略牡潴瑭桥敮汴椠慯汦?捡慤湶捡敮牣?慤渠?潥灵敲湯?汮慤扯散汲??獥椠湴杵汭敯?杲牳漠畡灳??灣桩慡獴敥?㈠?瑩牴楨愠汣孡?嵣???慩湤挠敳瑹?佤湲捯潭汥?㈨げ??????????????????扩牳?孤??嵰?偡潣睥汢敯獣?呮??卯慬牬睥慤爬?买???潥渠攳猠?剴???楛?敝琮?慌污??楥???渰?椱測搠椳爷攸挨琹?挰漸洩瀺愲爰椰猵漭渲‰漱昲?琼桢敲￣瑛漲砱楝挠楈瑡票?漠晎?猬甠湓楴瑡楤湬楥扲?慗湍搬?灚慯穮漠灒慔測椠戼?椾湥?洠敡瑬愼猯瑩愾琮椠捐?捡汳敥愠牡?捴敲汩污?爠敯湦愠汣?捳慰湬捡整物孮?崠???畣物????慮湥挠敡牮???づ????????????????????ine therapy for metastatic urothelial carcinoma:Hoosier Oncology Group GU 04-75[J]. J Clin Oncol,2011,29(12):1525-1530.
[18]	Pili R, QIN R, Flynn PJ, et al.A phase Ⅱ safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer[J]. Clin Genitourin Cancer,2013,11(4):477-483.
[19]	Gril B, Palmieri D, QIAN Y, et al. Pazopanib reveals a role for tumor cell BRaf in the prevention of HER2+ breast cancer brain metastasis[J]. Clin Cancer Res,2010, 17(1):142-153.
[20]	Palmieri D, Lockman PR, Thomas FC, et al.Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks[J]. Clin Cancer Res,2009, 15(19):6148-6157.
[21]	Podar K,Tonon G,Sattler M, et al. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma[J]. Proc Natl Acad Sci (USA), 2006, 103(51):19478-19483.
[22]	Grossniklaus HE, Ling JX,Wallace TM, et al.

Message Board

Progress of pazopanib in clinical applications and adverse drug reaction

doi: 10.3969/j.issn.1006-0111.2016.06.005

Abstract

References

Proportional views

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Related

Proportional views